RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed £40 billion by 2031, up from £38 billion. The revision reflects confidence in its expanding specialty medicines portfolio, late-stage pipeline, and upcoming product launches.
In 2024, GSK’s total revenue grew 7% at constant exchange rates to £31.4 billion, driven by a 19% surge in specialty medicine sales. Oncology revenue nearly doubled, while HIV and respiratory treatments posted double-digit gains. General medicines grew 6%, with Trelegy sales up 27%. However, vaccine revenue fell 4%, as Arexvy sales dropped 51%.
Despite strong growth, total operating profit declined 33% due to a £1.8 billion Zantac litigation settlement charge. Core operating profit rose 11%, and core earnings per share increased 10% to 159.3p, though total EPS fell 40% to 63.2p. GSK’s cash flow remained strong, generating £8 billion, reducing net debt to £13.1 billion from £15 billion.
Regionally, U.S. sales grew 6% to £16.4 billion, while European revenue rose 4% to £6.7 billion. International markets led growth, climbing 11% to £8.3 billion. The company continues expanding in specialty medicines, with rising demand for HIV and respiratory treatments and a growing oncology presence.
GSK has 71 specialty medicines and vaccines in development, with 19 in late-stage trials or regulatory review. Five major approvals are expected in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments.
For 2025, GSK expects turnover growth of 3%-5%, with core operating profit and EPS rising 6%-8%. The company also announced a £2 billion share buyback over 18 months and an increased dividend of 64p per share.
